McKESSON MCK
McKESSON FY 2025: revenue $359.1B, up 16%; diluted EPS $25.72
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000927653-25-000036
- Document
- 10-K
- Exhibit 4.16
- Warrants or notes
- Exhibit 10.23
- Material contract
- Exhibit 10.24
- Material contract
- Exhibit 10.26
- Material contract
Key figures from this report
These are the numbers McKESSON reported for the year ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$359.1B+16% from $309.0B in FY 202410-K income statement, on EDGAR
- Net income$3.3B+10% from $3.0B in FY 202410-K income statement, on EDGAR
- Diluted EPS$25.72+15% from $22.39 in FY 202410-K income statement, on EDGAR
- Cash and cash equivalents$5.7B+24% from $4.6B in FY 202410-K balance sheet, on EDGAR
- Cash from operations$6.1B+41% from $4.3B in FY 202410-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 5122 and related industry codes: the same peer list as the financial tables.
- Cardinal Health CAH public float $48.2B, Dec 31, 2025
- Cencora COR public float $37.9B, Mar 31, 2025, over 18 months old
- Herbalife HLF public float $762M, Jun 30, 2025
- Nu Skin Enterprises NUS public float $390M, Jun 30, 2025
- DataMeds AI MEDS public float $27M, Jun 30, 2025